The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | LADIE study: NSCLC in women
Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, highlights data published on the IFCT-1003 LADIE study. This phase II randomized study evaluated the treatment of patients with EGFR-TKI alongside fulvestrant, an anti-estrogen therapy, in women with non-squamous advanced stage non-small cell lung cancer. The study concluded that adding fulvestrant to EGFR-TKI is feasible, but not associated with prolonged PFS regardless EGFR status. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
